Related Experiment Video

Updated: Nov 4, 2025

Preparation of Naringenin Solution for In Vivo Application
08:18

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

3.5K

Novel advances in inhibiting advanced glycation end product formation using natural compounds

Qinghe Song1, Junjun Liu1, Liyuan Dong1

  • 1Endocrine and Metabolic Diseases Hospital of Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences, 18877, Jingshi Rd., Jinan 250001, China.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|May 29, 2021
PubMed

Insights

Advanced glycation end products (AGEs) contribute to chronic diseases. Natural compounds show promise in inhibiting AGE formation through various mechanisms, potentially inspiring new drug discovery.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Metabolic Diseases

Background:

  • Advanced glycation end products (AGEs) are formed via nonenzymatic reactions between proteins/lipids and sugars.
  • AGE accumulation in vivo is linked to the pathogenesis of chronic metabolic diseases.
  • Understanding AGE formation and biological impact is crucial for disease management.

Purpose of the Study:

  • To elucidate the formation, classification, and biological effects of AGEs.
  • To review natural compounds that inhibit AGE formation.
  • To explore the therapeutic potential of natural antiglycation agents.

Main Methods:

  • Literature review of AGE formation pathways and biological effects.
  • Compilation and analysis of studies on natural AGE inhibitors.
  • Summary of mechanisms of action for natural antiglycation compounds.

Main Results:

  • AGEs are implicated in various chronic metabolic diseases.
  • Polyphenols, polysaccharides, terpenoids, vitamins, and alkaloids exhibit AGE inhibitory properties.
  • Mechanisms include free radical scavenging, metal chelation, and carbonyl trapping.

Conclusions:

  • Natural compounds possess significant antiglycation activity.
  • Low natural abundance limits current clinical use but highlights potential for drug discovery.
  • Natural compound frameworks offer valuable leads for developing novel therapeutic strategies against AGE-related diseases.
Keywords:
AGE formation inhibitorsAdvanced glycation end productsAntiglycationNatural compounds

More Related Videos

Plate-based Large-scale Cultivation of Caenorhabditis elegans: Sample Preparation for the Study of Metabolic Alterations in Diabetes05:08

Plate-based Large-scale Cultivation of Caenorhabditis elegans: Sample Preparation for the Study of Metabolic Alterations in Diabetes

Published on: August 24, 2018

6.5K
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.4K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
316
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
345
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
513
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
345
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
383
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
87.5K